News | January 20, 2022
Natco Pharma signs agreement with Medicines Patent Pool
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
First launches expected in H1 2022
They will commercialize molnupiravir in the international markets
CliniSys has the proven ability to deliver 100s of millions of medical results a month to enable pandemic-scale population disease surveillance across the globe
The acquisition would enable addition of established brands with high recall amongst healthcare professionals, especially in the vitamins, minerals and supplements category
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
It provides Covid-19 detection and Omicron surveillance in less than two hours
The tie-up combines Abbisko Therapeutics’ proprietary drug discovery platform with Lilly’s disease and discovery expertise
Narayanan to lead SeQuent through next phase of consolidation and growth
The company has 47 ANDA's pending approval with the U.S.FDA
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
